Payment overview · 2025
General Payments
$538.57
20 reported records · 10 companies
Healthcare provider profile · identity verified
David John Stansfield, DO
Allopathic & Osteopathic Physicians|Family Medicine · HILLSBORO, MO · NPI 1619963253
Verified facts
What the public records show
CMS Open Payments records show David John Stansfield, DO received $538.57 in general payments during 2025 across 20 reported records.
Amgen Inc. accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Otezla, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $169.13 | 31.4% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $116.33 | 21.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.58 | 10.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.91 | 9.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.19 | 7.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.84 | 6.3% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.78 | 4.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.24 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.17 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.40 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.57 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $116.33 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.84 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.97 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.97 | 4 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 65 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 19 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 653 | 177 |
| Lisinopril | Lisinopril | 497 | 126 |
| Simvastatin | Simvastatin | 446 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 90 |
| Metformin Hcl | Metformin Hcl | 317 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 307 | 72 |
| Alprazolam | Alprazolam | 280 | 52 |
| Losartan Potassium | Losartan Potassium | 261 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 60 |
| Lorazepam | Lorazepam | 228 | 43 |
| Omeprazole | Omeprazole | 227 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 206 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 52 |
| Furosemide | Furosemide | 197 | 61 |
| Tramadol Hcl | Tramadol Hcl | 180 | 35 |
| Gabapentin | Gabapentin | 157 | 46 |
| Famotidine | Famotidine | 154 | 24 |
| Sertraline Hcl | Sertraline Hcl | 151 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 146 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 24 |
| Prednisone | Prednisone | 132 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 129 | 28 |
| Baclofen | Baclofen | 114 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 113 | 27 |
| Trazodone Hcl | Trazodone Hcl | 112 | 25 |
| Pregabalin | Pregabalin | 108 | 23 |
| Meloxicam | Meloxicam | 105 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 19 |
| Levetiracetam | Levetiracetam | 101 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 99 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 27 |
| Carvedilol | Carvedilol | 93 | 20 |
| Celecoxib | Celecoxib | 86 | 18 |
| Allopurinol | Allopurinol | 82 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 14 |
| Olanzapine | Olanzapine | 73 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 72 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | suppressed |
| Risperidone | Risperidone | 71 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 22 |
| Alendronate Sodium | Alendronate Sodium | 68 | 17 |
| Montelukast Sodium | Montelukast Sodium | 68 | 19 |
| Donepezil Hcl | Donepezil Hcl | 67 | 15 |
| Phenobarbital | Phenobarbital | 67 | suppressed |
| Diazepam | Diazepam | 66 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 51 |
| Mounjaro | Tirzepatide | 65 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 64 | suppressed |
| Glimepiride | Glimepiride | 63 | 19 |
| Temazepam | Temazepam | 63 | suppressed |
| Jardiance | Empagliflozin | 62 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 16 |
| Azithromycin | Azithromycin | 60 | 41 |
| Finasteride | Finasteride | 60 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | 11 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 11 |
| Atenolol | Atenolol | 47 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | suppressed |
| Eliquis | Apixaban | 47 | suppressed |
| Ketoconazole | Ketoconazole | 47 | 12 |
| Linzess | Linaclotide | 47 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 15 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | 12 |
| Potassium Chloride | Potassium Chloride | 43 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 29 |
| Farxiga | Dapagliflozin Propanediol | 40 | 12 |
| Ozempic | Semaglutide | 40 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 14 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Naproxen | Naproxen | 33 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 21 |
| Ibuprofen | Ibuprofen | 32 | 11 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 12 |
| Betamethasone Valerate | Betamethasone Valerate | 29 | 17 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 11 |
| Zonisamide | Zonisamide | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 15 |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 17 |
| Topiramate | Topiramate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Phenytoin | Phenytoin | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Loxapine | Loxapine Succinate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.57 · 20 records | Amgen Inc. | AIRSUPRA, GLASSIA, INGREZZA, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, STRENSIQ, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error